Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.
Actively Recruiting
Researchers are evaluating ways to improve cervical cancer screening and treatment among women living with HIV WLHIV in Nigeria, a country with a large population affected by HIV and high rates of cervical cancer deaths. This study compares two sets of strategies to integrate cervical cancer services into existing HIV care programs, aiming to enhance screening, treatment, referral completion, and retention in care. The goal is to improve health outcomes and life expectancy for WLHIV facing both HIV and cervical cancer. The trial involves two groups receiving different implementation strategies. One group follows Core Implementation Strategies including ongoing consultation, educational meetings, strengthening referral systems, and preparing patients to participate actively. The other group receives these Core strategies plus enhanced approaches like community engagement through the Health Beginning Initiative Model and the use of Smart Cards to support patient involvement. The study uses a cluster randomized design to compare these approaches. Participants are women living with HIV aged 25 to 64 years. Researchers will monitor how well the cervical cancer screening and treatment services reach patients and how sustainable these services are over time. Outcomes include measuring reach at 12 months after enrollment and sustainment near study completion, along with assessing cervical cancer screening and treatment effectiveness 15 months after treating pre-invasive cancer. The study will track participant progress and service delivery throughout the study period ending in 2027.
Actively Recruiting
Obesity is a major global health concern linked to heart disease, type 2 diabetes, and some cancers. This study is evaluating how metformin, a diabetes medication, affects weight loss, cardiovascular risk, and insulin resistance in obese Black Nigerian adults without diabetes. Researchers aim to understand metformins impact in this population, which may respond differently due to genetic and environmental factors. Participants will be randomly assigned to take either metformin extended release tablets, starting at 500 mg once daily and increasing up to 1500 mg daily, or a matching placebo that looks identical. The trial is blinded and placebo-controlled to fairly compare outcomes over two years. During the 24-month study, participants will have their weight, waist size, waist-to-hip ratio, cardiovascular risk, and insulin resistance regularly measured. Safety and medication adherence will be monitored throughout. This long-term follow-up will help determine metformins effects on obesity-related health measures in this population.
Actively Recruiting
Healthy Volunteer
Researchers are investigating the genetic basis of Type 2 Diabetes T2D and related conditions among the Yoruba people in Ibadan, Nigeria, as part of a broader effort to understand how genetic and lifestyle factors contribute to T2D and its complications. This observational study aims to identify genetic variants linked to diabetes risk and to explore whether variants found in European populations also affect West Africans. The study also seeks to develop a large-scale genetic resource for future research and to describe cardiometabolic traits in diverse African populations. Participants include 300 unrelated cases of T2D and 300 matched controls without diabetes from the Yoruba ethnic group. Both newly diagnosed and treated T2D patients are enrolled. The study involves collecting blood and urine samples, measuring blood pressure and body composition, conducting eye exams, and administering questionnaires. Genetic analyses, including a genome-wide association study GWAS and resequencing of candidate genes, will be performed using samples processed in Nigeria and at the National Institutes of Health. During participation, individuals will undergo several assessments such as finger prick blood glucose tests, confirmatory fasting glucose tests when needed, and anthropometric measurements. Researchers will also perform eye examinations and gather detailed health information through questionnaires. The study will monitor a range of outcomes including T2D presence, hypertension, obesity, metabolic syndrome, and related kidney and lipid conditions. Participation involves initial testing and sample collection, with DNA analysis and genetic studies conducted subsequently, supporting ongoing research in diabetes genetics.
Actively Recruiting
This research aims to collect real-world data on patients with type 2 diabetes, hypertension, heart failure, and chronic kidney disease. It focuses on understanding patient characteristics, disease management, healthcare use, and outcomes across many countries. The study is an observational registry that includes patients seen in regular clinical practice worldwide. Participants are grouped based on their main condition or comorbidities, including type 2 diabetes, hypertension, chronic kidney disease, or heart failure. Data is collected both retrospectively and prospectively using a cloud-based electronic case report form accessible to investigators and a scientific committee. The registry is open to all physicians managing these conditions globally. Participants contribute information about their health status, treatments, and clinical measurements over time. Researchers gather demographic data, disease history, lab tests, imaging, medication use, healthcare visits, and outcomes such as hospitalizations and complications. The study measures many health indicators at baseline and averages over three years to understand care quality and disease progression. Participation can last until the study ends in 2030.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating two combination interventions aimed at addressing adolescent HIV infection among youth aged 15 to 24 in Nigeria. These parallel 48-week hybrid effectiveness and implementation trials focus on improving HIV case finding and HIV treatment outcomes, particularly among young men who have sex with men YMSM. The study aims to identify youth living with HIV, link them to care, and support medication adherence and viral suppression in newly diagnosed individuals. The first intervention is a single-arm trial focusing on HIV case finding and linkage to care, using peer navigation and motivational interviewing to encourage HIV testing and pre-exposure prophylaxis PrEP uptake among those who test negative. The second is a randomized controlled trial comparing a combination HIV treatment intervention involving peer support and SMS reminders to standard care adherence support among youth newly starting antiretroviral therapy ART. Participants will be engaged over 48 weeks, with assessments including HIV testing, linkage to care, ART adherence, and viral load monitoring. Researchers will collect data on intervention effectiveness and implementation success, measuring outcomes such as HIV-positive serostatus, viral suppression, linkage to HIV care, and PrEP initiation. The study includes behavioral components like social media outreach and peer navigation to promote testing and treatment adherence.
Actively Recruiting
Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.
Actively Recruiting
This research aims to train radiologists in Nigeria to perform ultrasound-guided breast biopsies for breast cancer diagnosis. The study evaluates the use of mobile health mHealth devices to provide practical and sustainable training for radiologists. This approach is intended to improve the accuracy of breast cancer diagnosis compared to traditional methods used in Nigerian hospitals. Women who have a solid mass on breast ultrasound that is suspicious for breast cancer will be involved in the study. Instead of the usual blind biopsy or surgical excision commonly performed, participants will undergo an ultrasound-guided breast biopsy by trained radiologists using mHealth technology. This procedure is the standard of care in the United States due to its higher accuracy. Participants will be monitored over a one-year period to measure the number of successful ultrasound-guided breast biopsies performed. The study includes assessments related to biopsy procedures and the implementation of this technology into clinical practice. Participant involvement includes undergoing the biopsy procedure and being part of the evaluation of this training methods effectiveness and feasibility.